Notice · For research and educational reference. Not medical advice. Intended for licensed professionals. Nothing on this site is offered for sale other than informational access.

All Info Peptides
All monographs

Growth Hormone Secretagogues

CJC-1295

Also known as · DAC:GRF · Modified GRF (1-29)

Overview

A growth-hormone-releasing hormone analogue. The DAC variant covalently binds plasma albumin via a maleimidopropionic-acid linker, extending circulating half-life to roughly a week in preclinical work.

Research profile · for clinicians

Based on research: studied as a long-acting driver of the body's own growth-hormone pulses. The DAC variant binds circulating albumin so a single dose sustains GHRH-receptor tone across roughly a week in preclinical work, elevating baseline GH and IGF-1 output without introducing exogenous GH.

Mechanism of action

Agonism at the GHRH receptor on pituitary somatotrophs promotes endogenous GH synthesis and pulsatile release; albumin conjugation slows renal clearance.

Research record

  • [01]Phase I pharmacokinetics in healthy volunteers (Teichman et al., 2006).
  • [02]Combined administration with ghrelin-receptor agonists in preclinical models.

Selected references

  • Prolonged stimulation of GH and IGF-1 by CJC-1295

    J. Clin. Endocrinol. Metab., 2006